Arbutus Biopharma Corporation ABUS Gain (loss) on available-for-sale debt securities

Gain (loss) on available-for-sale debt securities at other companies

Flywire CorporationFLYW

-$34K+73.6%

ImmunomeIMNM

$0+100%

Vera TherapeuticsVERA

-$942K-461%

Grand Canyon EducationLOPE

-$696K-9,843%

First Financial BanksharesFFIN

$0—

ZymeworksZYME

$95K-62.5%

Other financials

Income statement

See full

Revenue$179.1M+10,055%

Operating income$168.9M+757%

Net income$169.7M+792%

EPS (diluted)$0.87+769%

Balance sheet

See full

Cash & equivalents$23.7M-36.1%

Total debt$631.0K-46.9%

Total equity$260.2M+229%

Total assets$277.2M+137%

Cash flow

See full

Operating cash flow-$8.1M+39.4%

CapEx--100%

Free cash flow-$4.7M+55.0%

Valuation

See full

Market cap$871.14M+32.6%

Enterprise value$848.07M+36.6%

P/E5.4×—

P/S4.6×-98.0×

Profitability

See full

Operating margin81.7%+42.1pp

Net margin84%+43.4pp

FCF margin-281.5%-119pp

Returns & leverage

See full

Return on equity94.7%+65.1pp

Debt / equity0×0.0×

Current ratio54.3×+48.3×

Where this comes from

Reported directly by Arbutus Biopharma Corporation in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss.

The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arbutus Biopharma Corporation's gain (loss) on available-for-sale debt securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Arbutus Biopharma Corporation's gain (loss) on available-for-sale debt securities?: Arbutus Biopharma Corporation (ABUS) reported gain (loss) on available-for-sale debt securities of -$97K in Q1 2026.
How has Arbutus Biopharma Corporation's gain (loss) on available-for-sale debt securities changed year-over-year?: Arbutus Biopharma Corporation's gain (loss) on available-for-sale debt securities decreased by 212.9% year-over-year, from -$31K to -$97K.